Author

Sarah Elizabeth Holy

Observed names: Sarah E. Holy, Sarah Holy, Sarah E. Holy

Institution: Retina Consultants of Texas

Observed institutions: Retina Consultants of Texas, Scott & White Memorial Hospital

OpenAlex ID: A5013380546

Perioperative Ischemic Optic Neuropathy

2009 · Sarah E. Holy, Jonathan H. Tsai, et al. · Anesthesiology · 73

Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti–Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema

2018 · Lee M. Jampol, Adam R. Glassman, et al. · Ophthalmology · 43

Lapses in Care Among Patients Assigned to Ranibizumab for Proliferative Diabetic Retinopathy

2021 · Maureen G. Maguire, Danni Liu, et al. · JAMA Ophthalmology · 31

Intraocular Pressure–Related Events After Anti–Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion

2021 · Ahmad A. Aref, Ingrid U. Scott, et al. · JAMA Ophthalmology · 14

Cost-Utility Comparison of Bevacizumab and Aflibercept in the Treatment of Central or Hemiretinal Vein Occlusion in the SCORE2 Trial

2023 · Steven M. Kymes, Neal L. Oden, et al. · JAMA Ophthalmology · 10

Baseline Characteristics and Outcomes After Anti–Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion

2022 · Ingrid U. Scott, Neal L. Oden, et al. · JAMA Ophthalmology · 6

MAGIC: Study Design and Rationale for the Phase 2 Clinical Trial of Faricimab for Non-Proliferative Diabetic Retinopathy

2026 · Avery W. Zhou, Ryan A. Sahraravand, et al. · Ophthalmologica

Works count: 7

Citation count: 177

H-index: 6

I10-index: 5